June Sherie Almenoff, Director at NeuBase Therapeutics, holds 1.00K shares in Avalo Therapeutics (Ticker: AVTX), holds 13.18K shares in Brainstorm Cell Therapeutics (Ticker: BCLI), holds 900.00 shares in 9 Meters Biopharma (Ticker: NMTRQ). Most recently, June Sherie Almenoff Bought ― shares of Avalo Therapeutics on Nov 14, 2024 for an estimated value of 12.74K.
What was June Sherie Almenoff’s latest transaction?
June Sherie Almenoff latest transaction was an Informative Buy of $12.74K.
What was June Sherie Almenoff's most profitable transaction?
June Sherie Almenoff’s most profitable transaction was an Informative Buy of BCLI stock on January 8, 2019. The return on the trade was 27.60%.
What is June Sherie Almenoff's role in NeuBase Therapeutics?
June Sherie Almenoff's role in NeuBase Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.